Latest News

Epigenomics AG: New Clinical Data for Septin9 Colorectal Cancer Blood Test Presented at UEGW

Independent validation of laboratory test used in PRESEPT Study shows that the test finds 86% of the cancers

27.10.2010

Berlin, Germany, and Seattle, WA, U.S.A.

Contact Epigenomics AG

Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 368
pr@epigenomics.com
www.epigenomics.com

Notes to Editors

About Epigenomics

www.epigenomics.com.

About the Septin9 Biomarker and Colorectal Cancer Blood Tests